Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Buy" by Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has been given a consensus rating of "Buy" by the nine ratings firms that are presently covering the stock, MarketBeat reports. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $23.71.

Several equities analysts recently weighed in on the company. Citigroup reiterated an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. Wall Street Zen upgraded Zevra Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Saturday. HC Wainwright assumed coverage on Zevra Therapeutics in a report on Wednesday, July 2nd. They issued a "buy" rating and a $26.00 price objective on the stock. Finally, Cantor Fitzgerald raised their price objective on Zevra Therapeutics from $25.00 to $29.00 and gave the stock an "overweight" rating in a report on Thursday, July 10th.

Zevra Therapeutics Trading Down 3.7%

NASDAQ ZVRA traded down $0.47 during trading hours on Tuesday, hitting $12.32. 1,605,950 shares of the company's stock were exchanged, compared to its average volume of 730,238. The business's 50 day moving average is $9.36 and its 200-day moving average is $8.29. Zevra Therapeutics has a 12-month low of $5.45 and a 12-month high of $13.16. The firm has a market capitalization of $673.66 million, a P/E ratio of -6.48 and a beta of 1.97. The company has a debt-to-equity ratio of 1.46, a quick ratio of 2.93 and a current ratio of 3.02.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.15. Zevra Therapeutics had a negative return on equity of 201.05% and a negative net margin of 226.78%. The firm had revenue of $20.40 million for the quarter, compared to the consensus estimate of $16.96 million. During the same period in the prior year, the business posted ($0.40) earnings per share. As a group, analysts anticipate that Zevra Therapeutics will post -1.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Zevra Therapeutics

A number of large investors have recently modified their holdings of ZVRA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Zevra Therapeutics by 6.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company's stock valued at $238,000 after buying an additional 1,812 shares during the period. Invesco Ltd. raised its holdings in shares of Zevra Therapeutics by 19.6% during the 4th quarter. Invesco Ltd. now owns 18,384 shares of the company's stock valued at $153,000 after buying an additional 3,007 shares during the period. Corebridge Financial Inc. raised its holdings in shares of Zevra Therapeutics by 16.9% during the 4th quarter. Corebridge Financial Inc. now owns 26,294 shares of the company's stock valued at $219,000 after buying an additional 3,801 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Zevra Therapeutics by 2.6% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 153,331 shares of the company's stock valued at $1,148,000 after buying an additional 3,827 shares during the period. Finally, Squarepoint Ops LLC raised its holdings in shares of Zevra Therapeutics by 36.1% during the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock valued at $138,000 after buying an additional 4,384 shares during the period. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.